

DAFTAR PUSTAKA

- Aberg, J. A., Lacy, C., Armstrong, L., Goldman, M., Lance, L. L., 2009, *Drug Information Handbook 17th Edition*, American Pharmacist Association, Washington DC.
- Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J. *et al.*, 2011, Azithromycin for prevention of exacerbations of COPD, *New England Journal of Medicine*, 365(8): 689-698.
- American Lung Association, 2022, *COPD Causes and Risk Factors*, dari www.lung.org, diakses pada November 2022.
- Anzueto, A., Miravittles, M., 2017, Pathophysiology of dyspnea in COPD, *Postgraduate Medicine*, 129(3): 366-374.
- Appleton, S., Jones, T., Poole, P., Pilotto, L., Adams, R., Lasserson, T. J., Smith, B., Muhammad, J., 2006, Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease, *Cochrane Database of Systematic Reviews*, (3): CD006101.
- Appleton, S., Jones, T., Poole, P., Pilotto, L., Adams, R., Lasserson, T. J., Smith, B., Muhammed, J., 2006, Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease, *Cochrane Database of Systematic Reviews*, 2: CD001387.
- Appleton, S., Poole, P., Smith, B., Veale, A., Lasserson, T. J., Chan, M. M., 2006, Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease, *Cochrane database of systematic reviews*, 3(3): CD001104.
- Asyrof, A., Arisdiani, T., Aspihan, M., 2021, Karakteristik dan kualitas hidup pasien Penyakit Paru Obstruksi Kronis (PPOK), *Jurnal Penelitian dan Pemikiran Ilmiah Keperawatan*, 7(1): 13-21.
- Barnes, P. J., 2013, Theophylline, *American Journal of Respiratory and Critical Care Medicine*, 188(8): 901-906.

- Barnes, P. J., 2016, Inflammatory mechanisms in patients with chronic obstructive pulmonary disease, *Journal of Allergy and Clinical Immunology*, 138(1): 16-27.
- Beeh, K. M., Beier, J., 2010, The Short, the Long, and the “Ultra-Long”: Why Duration of Bronchodilator Action Matters in Chronic Obstructive Pulmonary Disease, *Advances in Therapy*, 27(3): 150-159.
- Belchamber, K. B. R., Thomas, C. M. R., Dunne, A. E., Barnes, P. J., Donnelly, L. E., 2018, Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function, *International Journal of Chronic Obstructive Pulmonary Disease*, 13: 2883-2897.
- Boorsma, M., Lutter, R., van de Pol, M. A., Out, T. A., Jansen, H. M., Jonkers, R. E., 2008, Long-Term Effects of Budesonide on Inflammation Status in COPD, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 5(2): 97-104.
- Bowdish, D. M. E., 2019, The Aging Lung, *CHEST*, 155(2): 391-400.
- Brashier, B. B., Kodgule, R., 2012, Risk Factors and Pathophysiology of Chronic Obstructive Pulmonary Disease (COPD), *The Journal of the Association of Physicians of India*, 60: 17-21.
- Cazzola, M., Rogliani, P., Novelli, L., Matera, M. G., 2013, Inhaled corticosteroids for chronic obstructive pulmonary disease, *Expert Opinion on Pharmacotherapy*, 14(18): 2489-99.
- Celli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., Buist, A. S., Calverley, P. M. A. *et al.*, 2004, Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper, *European Respiratory Journal*, 23: 932-946.
- Chong, J., Karner, C., Poole, P., 2012, Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease, *Cochrane Database of Systematic Reviews*, (9): CD009157.
- Courtney, C., Dransfield, M. T., Bourbeau, J., Jones, P. W., Hanania, N. A., Mahler, D. A., Vestbo, J., Wachtel, A., Martinez, F. J., Barnhart, F., Lettis, S., Calverley, P. M. A., 2015, Pneumonia risk with inhaled fluticasone furoate

- and vilanterol compared with vilanterol alone in patients with COPD, *Annals of the American Thoracic Society*, 12(1): 27-34.
- Dahlan, M. S., 2010, *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*, Salemba Medika, Jakarta.
- Decramer, M. L., Chapman, K. R., Dahl, R., Frith, P., Devouassoux, G., Fritscher, C. *et al.*, 2013, Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study, *Lancet Respiratory Medicine*, 1(7): 524-533.
- DeMeo, D. L., Silverman, E. K., 2004, **α_1 -Antitrypsin deficiency 2: Genetic aspects of α_1 -antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk**, *Thorax*, 59: 259-264.
- DiPiro, J. T., Yee, G. C., Posey, L. M., 2020, *Pharmacotherapy A Pathophysiologic Approach Eleventh Edition*, McGraw-Hill Professional, New York.
- Domej, W., Oettl, K., Renner, W., 2014, Oxidative stress and free radicals in COPD – implications and relevance for treatment, *International Journal of Chronic Obstructive Pulmonary Disease*, 9: 1207-1224.
- Donohue, J. F., 2005, Combination Therapy for Chronic Obstructive Pulmonary Disease, *Proceedings of the American Thoracic Society*, 2: 272-281.
- Dransfield, M. T., Bailey, W., Crater, G., Emmett, A., O'Dell, D. M., Yawn, B., 2011, Disease severity and symptoms among patients receiving monotherapy for COPD, *Primary Care Respiratory Journal*, 20(1): 46-53.
- Ejiofor, S., Turner, A. M., 2013, Pharmacotherapies for COPD, *Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine*, 7: 17-34.
- Emir, F., Bansal, V., Gupta, E., Scanlon, P. D., 2016, Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD; Systematic Review and Meta-Analysis, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 13(3): 312-326.
- Falk, J. A., Minai, O. A., Mosenifar, Z., 2008, Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease, *Proceedings of the American Thoracic Society*, 5(4): 506-512.

- Global Initiative for Asthma (GINA), 2021, *Global Strategy for Asthma Management and Prevention*, dari <https://ginasthma.org>, diakses pada Januari 2023.
- Global Initiative for Chronic Obstructive Lung Disease (GICOPD), 2001, *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease*, National Institutes of Health, National Heart, Lung, and Blood Institute. Publication number 2701.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2019, *Global Strategy for the Diagnosis, Management, and Prevention of COPD (2019 Report)*, dari <http://www.goldcopd.org>, diakses pada Oktober 2022.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2020, *Global Strategy for the Diagnosis, Management, and Prevention of COPD (2020 Report)*, dari <http://www.goldcopd.org>, diakses pada Oktober 2022.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2022, *Global Strategy for the Diagnosis, Management, and Prevention of COPD (2022 Report)*, dari <http://www.goldcopd.org>, diakses pada Oktober 2022.
- Gosens, R., Zaagsma, J., Meurs, H., Halayko, A. J., 2006, Muscarinic receptor signaling in the pathophysiology of asthma and COPD, *Respiratory Research*, 7(1): 73.
- Gundry, S., 2019, COPD 1: pathophysiology, diagnosis and prognosis, *Nursing Times [online]*, 116(4): 27-30.
- Hanania, A., Sharafkhaneh, A., 2011, *COPD: A Guide to Diagnosis and Clinical Management*, Humana Press, New York.
- Hillas, G., Perlikos, F., Tsiligianni, I., Tzanakis, N., 2015, Managing comorbidities in COPD, *International Journal of COPD*, 10: 95-109.
- Iheanacho, I., Zhang, S., King, D., Rizzo, M., Ismaila, A. S., 2020, Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review, *International Journal of Chronic Obstructive Pulmonary Disease*, 15: 439-460.
- Ikawati, Z., 2016, *Penatalaksanaan Terapi Penyakit Sistem Pernafasan*, Bursa Ilmu, Yogyakarta.

- Irwin, R. S., Richardson, N. D., 2006, Side effects with inhaled corticosteroids: the physician's perception, *Chest*, 130(1 Suppl): 41S-53S.
- Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito M., Barnes, P. J., Adcock, I. M., 2006, Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression, *Journal of Experimental Medicine*, 203(1):7-13.
- Jenkins, C. R., Chapman, K. R., Donohue, J. F., Roche, N., Tsiligianni, I., Han, M. K., 2017, Improving the Management of COPD in Women, *CHEST*, 151(3): 686-696.
- Jones, P. W., Harding, G., Berry, P., Wiklund, I., Chen, W. H., Kline Leidy, N., 2009, Development and first validation of the COPD Assessment Test, *European Respiratory Journal*, 34(3): 648-54.
- Jones, P. W., Harding, G., Wiklund, I., Berry, P., Tabberer, M., Yu, R., Leidy, N. K., 2012, Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation, *Chest*, 142(1): 134-140.
- Kalola, U. K., Ambati, S., 2022, *Budesonide*, StatPearls Publishing, Treasure Island (FL).
- Kementerian Kesehatan Republik Indonesia, 2013, *Riset Kesehatan Dasar (RISKESDAS) 2013*, Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan Republik Indonesia, 2016, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Ko, F. W., Chan, K. P., Hui, D. S., Goddard, J. R., Shaw, J. G., Reid, D. W., Yang, I. A., 2016, Acute exacerbation of COPD, *Respirology*, 21: 1152-1165.
- Koskela, J., Kilpelainen, M., Kupiainen, H., Mazur, W., Sintonen, H., Boezen, M., Lindqvist, A., Postma, D., Laitinen, T., 2014, Co-morbidities are the key nominators of the health-related quality of life in mild and moderate COPD, *BMC Pulmonary Medicine*, 14: 102.

- Kwon, N., Amin, M., Hui, D. S., Jung, K. S., Lim, S. Y., Ta, H. D., Thai, T. T. L., Yunus, F., Jones, P. W., 2013, Validity of the COPD Assessment Test Translated Into Local Languages for Asian Patients, *Chest*, 143(3): 703-710.
- Lanza, F. C., Castro, R. A. S., de Camargo, A. A., Zanatta, D. J. M., Rached, S., Athanazio, R., Cukier, A., Stelmach, R., Corso, S. D., 2018, COPD Assessment Test (CAT) is a Valid and Simple Tool to Measure the Impact of Bronchiectasis on Affected Patients, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 15(5): 512-519.
- Lee, C. -H., Lee, M. -C., Lin, H. -H., Shu, C. -C., Wang, J. -Y., Lee, L. -N., Chao, K. -M., 2012, Pulmonary Tuberculosis and Delay in Anti-Tuberculosis Treatment Are Important Risk Factors for Chronic Obstructive Pulmonary Disease, *PLoS ONE*, 7(5): e37978.
- Li, H., He, G., Chu, H., Zhao, L., Yu, H., 2003, A step-wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD, *Respirology*, 8: 199-204.
- Liu, C., Cheng, W., Zeng, Y., Zhou, Z., Zhao, Y., Duan, J., Wang, R., Sun, T., Li, X. *et al.*, 2020, Different Characteristics of Ex-Smokers and Current Smokers with COPD: A Cross-Sectional Study in China, *International Journal of Chronic Obstructive Pulmonary Disease*, 15: 1613-1619.
- LoMauro, A., Aliverti, A., 2018, Sex differences in respiratory function, *Breathe*, 14: 131-140.
- Lundback, B., Lindberg, A., Lindstrom, M., Ronmark, E., Jonsson, A. C., Jonsson, E., Larsson, L. -G., Andersson, S., Sandstrom, T., Larsson, K., 2003, Not 15 But 50% of smokers develop COPD? – Report from the Obstructive Lung Disease in Northern Sweden Studies, *Respiratory Medicine*, 97: 115-122.
- Mamary, A. J., Criner, G. J., 2009, Tiotropium bromide for chronic obstructive pulmonary disease, *Expert Review of Respiratory Medicine*, 3(3): 211-220.
- Mammen, M. J., Lloyd, D. R., Kumar, S., Ahmed, A. S., Pai, V., Kunadharaju, R., Gupta, S., Nici, L., Aaron, S. D., Alexander, P. E., 2020, Triple Therapy

versus Dual or Monotherapy with Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease, *Annals of the American Thoracic Society*, 17(10): 1308-1318.

Manihuruk, D., Pandia, P., Tarigan, A., Eyanoer, P. C., 2015, Nilai *COPD Assessment Test* dan *Modified Medical Research Council Dyspneu Scale* dengan Derajat Obstruksi dan Eksaserbasi Penyakit Paru Obstruktif Kronik, *Jurnal Respirologi Indonesia*, 35(4): 218-222.

Mannino, D. M., Buist, A. S., 2007, Global burden of COPD: risk factors, prevalence, and future trends, *Lancet*, 370: 765-773.

Marin, A., Monso, E., Garcia-Nunez, M., Sauleda, J., Nogjera, A., Pons, J., *et al.*, 2010, Variability and effects of bronchial colonization in patients with moderate COPD, *The European Respiratory Journal*, 35(2): 295-302.

Martinez, F. J., Calverley, P. M. A., Goehring, U. M., Brose, M., Fabbri, L. M., Rabe, K. F., 2015, Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial, *Lancet*, 385(9971): 857-866.

Maselli, D. J., Hardin, M., Christenson, S. A., Hanania, N. A., Hersh, C. P., Adams, S. G. *et al.*, 2019, Clinical Approach to the Therapy of Asthma-COPD Overlap, *CHEST*, 155(1): 168-177.

Molen, T., Miravittles, M., Kocks, J. W. H., 2013, COPD management: role of symptom assessment in routine clinical practice, *International Journal of COPD*, 8: 461-471.

Molfino, N. A., Zhang, P., 2006, A meta-analysis on the efficacy of oral theophylline in patients with stable COPD, *International Journal of COPD*, 1(3): 261-266.

Montuschi, P., 2006, Pharmacological treatment of chronic obstructive pulmonary disease, *International Journal of COPD*, 1(4): 409-423.

Moreno, D., Barroso, J., Garcia, A., 2015, Vaccines for Patients with COPD, *Recent Patents on Inflammation & Allergy Drug Discovery*, 9(1): 23-30.

- Newman, S. P., 2005, Inhaler treatment options in COPD, *The European Respiratory Review*, 14(96): 102-108.
- Ocejo, A., Correa, R., 2022, *Methylprednisolone*, StatPearls Publishing, Treasure Island (FL).
- Oelsner, E. C., Balte, P. P., Bhatt, S. P., Cassano, P. A., Couper, D., Folsom, A. R. Freedman, N. D. *et al.*, 2020, Lung Function Decline in Former Smokers and Low-Intensity Current Smokers: the NHLBI Pooled Cohorts Study, *Lancet Respiratory Medicine*, 8(1): 34-44.
- Oga, T., Nishimura, K., Tsukino, M., Sato, S., Hajiro, T., Mishima, M., 2003, A Comparison of the Effects of Salbutamol and Ipratropium Bromide on Exercise Endurance in Patients with COPD, *CHEST*, 123(6): 1810-1816.
- Papaioannou, M., Pitsiou, G., Manika, K., Kontou, P., Zarogoulidis, P., Sichletidis, L., Kioumis, I. P., 2014, COPD Assessment Test: A Simple Tool to Evaluate Disease Severity and Response to Treatment, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 11: 489-495.
- Patel, P., Saab, H., Aboeed, A., 2022, *Ipratropium*, StatPearls Publishing, Treasure Island (FL).
- Prescott, E., 2000, Tobacco-related diseases: the role of gender, *Dan Med Bull*, 47: 115-131.
- Putra, D. P., Bustamam, N., Chairani, A., 2016, Hubungan Berhenti Merokok dengan Tingkat Keparahan Penyakit Paru Obstruktif Kronik Berdasarkan GOLD 2013, *Jurnal Respirologi Indonesia*, 36(1): 20-7.
- Raissy, H. H., Kelly, H. W., Harkins, M., Szeffler, S. J., 2013, Inhaled Corticosteroids in Lung Diseases, *American Journal of Respiratory and Critical Care Medicine*, 187(8): 798-803.
- Ram, F. S. F., Jones, P., Jardim, J., Castro, A. A., Atallah, A. N., Lacasse, Y., Goldstein, R., Cendon, S., 2002, Oral theophylline for chronic obstructive pulmonary disease, *Cochrane Database of Systematic Reviews*, 3: CD003902.
- Ramos, F. L., Krahnke, J. S., Kim, V., 2014, Clinical issues of mucus accumulation in COPD, *International Journal of COPD*, 9: 139-150.

- Ritianingsih, N., Nurhayati, F., 2017, Lama Sakit Berhubungan dengan Kualitas Hidup Pasien Penyakit Paru Obstruksi Kronis (PPOK), *Jurnal Kesehatan Bakti Tunas Husada*, 17(1): 133-138.
- Roland, N. J., Bhalla, R. K., Earis, J., 2004, The local side effects of inhaled corticosteroids: current understanding and review of the literature, *Chest*, 126(1): 213-219.
- Sandman, Z., Iqbal, O. A., 2022, *Azithromycin*, StatPearls Publishing, Treasure Island (FL).
- Sari, C. P., Hanifah, S., Rosdiana, Annisa, Y., 2021, Efektivitas Pengobatan Pada Pasien Penyakit Paru Obstruksi Kronis (PPPOK) di Rumah Sakit Wilayah Yogyakarta, *Jurnal Manajemen dan Pelayanan Farmasi*, 11(4): 215-227.
- Sarkar, M., Srinivasa, Madabhavi, I., Kumar, K., 2017, Tuberculosis associated chronic obstructive pulmonary disease, *The Clinical Respiratory Journal*, 11: 285-295.
- Senderovich, H., Yendamuri, A., 2019, Management of Breathlessness in Palliative Care: Inhalers and Dyspnea – A Literature Review, *Rambam Maimonides Medical Journal*, 10(1): e0006.
- Sethi, S., Maloney, J., Grove, L., Wrona, C., Berenson, C. S., 2006, Airway Inflammation and Bronchial Bacterial Colonization in Chronic Obstructive Pulmonary Disease, *American Journal of Respiratory and Critical Care Medicine*, 173(9): 991-998.
- Shujaat, A., Bajwa, A. A., Cury, J. D., 2012, Pulmonary Hypertension Secondary to COPD, *Pulmonary Medicine*, 2012: 203952.
- Sibila, O., Laserna, E., Mortensen, E. M., Anzueto, A., Restrepo, M. I., 2013, Effects of Inhaled Corticosteroids on Pneumonia Severity and Antimicrobial Resistance, *Respiratory Care*, 58(9): 1489-1494.
- Silva, G. E., Sherrill, D. L., Guerra, S., Barbee, R. A., 2004, Asthma as a Risk Factor for COPD in a Longitudinal Study, *CHEST*, 126(1): 59-65.
- Silverman, E. K., Weiss, S. T., Drazen, J. M., Chapman, H. A., Carey, V., Campbell, E. J., Denish, P., Silverman, R. A., Celedon, J. C., Reilly, J. J., Ginns, L. C., Speizer, F. E., 2000, Gender-Related Differences in Severe,

- Early-Onset Chronic Obstructive Pulmonary Disease, *American Journal of Respiratory and Critical Care Medicine*, 162: 2152-2158.
- Singh, D., Donohue, J. F., Boucot, I. H., Barnes, N. C., Compton, C., Martinez, F. J., 2021, Future concepts in bronchodilation for COPD: dual- versus monotherapy, *European Respiratory Review*, 30: 210023.
- Sorheim, I. C., Johannessen, A., Gulsvik, A., Bakke, P. S., Silverman, E. K., DeMeo, D. L., 2010, Gender differences in COPD: are women more susceptible to smoking effects than men? *Thorax*, 65: 480-485.
- Tashkin, D. P., 2015, Smoking Cessation in Chronic Obstructive Pulmonary Disease, *Seminars in Respiratory and Critical Care Medicine*, 36(4): 491-507.
- Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M., 2008, A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease, *The New England Journal of Medicine*, 359(15): 1543-54.
- Tsiligianni, I. G., Molen, T., Moraitaki, D., Lopez, I., Kocks, J. W. H., Karagiannis, K., Siafakas, N., Tzanakis, N., 2012, Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ), *BMC Pulmonary Medicine*, 12:20.
- Uzun, S., Djamin, R. S., Kluytmans, A. J. W., Mulder, P. G. H., Veer, N. E., Ermens, A. A. M., Pelle, A. J., Hoogsteden, H. C., Aerts, J. G. J. V., Eerden, M. M., 2014, Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial, *Lancet Respiratory Medicine*, 2(5): 361-368.
- Vogelmeier, C. F., Roman-Rodriguez, M., Singh, D., Han, M. K., Rodriguez-Roisin, R., Ferguson, G. T., 2020, *Respiratory Medicine*, 166: 105938.
- Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Molken, M. P. M. H., Beeh, K. M., Rabe, K. F., Fabbri, L. M., 2011, Tiotropium versus salmeterol for the prevention of exacerbations of COPD, *New England Journal of Medicine*, 364(12): 1093-1103.

- Walters, J. A. E., Walters, E. H., Wood-Baker, R., 2005, Oral corticosteroids for stable chronic obstructive pulmonary disease, *Cochrane Database of Systematic Reviews*, 3: CD005374.
- Wardani, N., 2018, Perbedaan Pengaruh Penambahan *Diafragma Breathing* pada Mobilisasi Sangkar *Thoraks* terhadap Peningkatan *Ekspansi Thoraks* Penyakit Paru Obstruktif Kronis (PPOK), Skripsi, Fakultas Ilmu Kesehatan Universitas 'Aisyiyah Yogyakarta.
- Wedzicha, J. A., Singh, R., Mackay, A. J., 2014, Acute COPD exacerbations, *Clinics in Chest Medicine*, 35(1): 157-163.
- Wright, J. L., Levy, R. D. Churg, A., 2005, Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment, *Thorax*, 60: 605-609.
- Yang, M., Du, Y., Chen, H., Jiang, D., Xu, Z., 2019, Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials, *International Immunopharmacology*, 77: 105950.
- Yasin, N. M., Sunowo, J., Supriyanti, E., 2009, *Drug Related Problems (DRP)* dalam Pengobatan *Dengue Haemorrhagic Fever (DHF)* pada Pasien Pediatri, *Majalah Farmasi Indonesia*, 20(1): 27-34.
- Zulkarni, R., Nessa, N., Athifah, Y., 2019, Analisis Ketepatan Pemilihan dan Penentuan Regimen Obat pada Pasien Penyakit Paru Obstruktif Kronis (PPOK), *Jurnal Sains Farmasi & Klinis*, 6(2): 158-163.